Gentry Injection 1g (Ceftriaxone Sodium Hydrate)
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Celix Co., Ltd.
MFDS item code 201707090 · Notified 2017.09.15 · Insurance code 646203951
Treatment of infections in the respiratory system (pneumonia, bronchitis) and in the reproductive system (gonorrhea)
This medication is effective in treating various respiratory infections such as pneumonia and bronchitis. It is also used for infections in the otolaryngological region as well as kidney and urinary tract infections, and reproductive infections such as gonorrhea. It helps in the prevention of infections before and after surgeries, and is also suitable for the treatment of bone and joint infections. It is effective for infections of the skin, wounds, and soft tissues, as well as gastrointestinal infections, including peritonitis, cholecystitis, and cholangitis. It can be used for infections in immunocompromised patients and the treatment of meningitis, benefiting a wide variety of infections.
Adults and children over 12 years old should receive ceftriaxone at a dosage of 1–2g (potency) once daily via intravenous or intramuscular injection. In cases of severe diseases or infections caused by moderately susceptible pathogens, the dosage may be increased to 4g (potency) once daily. For the treatment of gonorrhea, a single intramuscular injection of 250mg (potency) is recommended. For preventing infections before and after surgery, a single dose of 1–2g (potency) should be administered 30–90 minutes prior to the procedure, depending on the risk of infection.
For children under 12 years old and infants, administer 20–80mg (potency) per kg of body weight once daily. For children over 50kg, administer the standard adult dosage. Administration should not exceed 50mg (potency) per kg of body weight.
This medication should not be mixed or administered simultaneously with solutions or drugs containing calcium. In particular, it should never be administered to newborns as it can form precipitates when mixed with calcium, posing a severe risk of adverse effects. It should not be given to patients with hypersensitivity to this drug or those allergic to cephalosporins or penicillins, or to specific local anesthetics. It is also contraindicated in premature infants and newborns with problems in bilirubin binding. This drug should be administered with caution in patients with a history of allergies or those with severe kidney disease, and dosage adjustments may be necessary. During administration, liver and kidney functions and blood conditions must be regularly monitored to detect adverse reactions early. This medication can cause side effects such as diarrhea, rashes, decreased blood cell counts, and elevated liver enzymes, so any unusual symptoms should be reported to healthcare professionals immediately. If severe allergic reactions or shock symptoms occur, administration must be immediately stopped, and emergency treatment sought. This drug may interact with other medications, so caution is needed, especially with diuretics, aminoglycoside antibiotics, and vitamin K antagonists. Women who are pregnant or breastfeeding should carefully consider the risks and benefits before using this medication. In children, especially newborns and premature infants, it should be avoided due to the risk of bilirubin encephalopathy. Elderly patients may experience side effects more easily due to decreased bodily functions, so care must be taken with dosage and administration intervals. While receiving this medication, care should be taken when driving or operating machinery to minimize the risk of accidents due to adverse effects such as dizziness. Calcium-containing solutions should not be mixed during administration, and the injection site should be thoroughly cleaned to prevent precipitation. Prepared solutions should be used as quickly as possible, and when stored, they should be used within the designated temperature and time for safety.
Urticaria, severe swelling (edema), shock, wheezing, severe allergic reactions, anaphylaxis, anaphylactoid reactions, severe skin reactions (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), symptoms due to ceftriaxone-calcium precipitation in the gallbladder, severe skin reactions, encephalopathy, acute renal failure, severe edema and urination abnormalities (frequent urination, oliguria), kernicterus, liver abnormalities (jaundice), sudden and severe
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to avoid exposure to air, and it is safest to store it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and prevent degradation.
A white to light yellow crystalline powder filled in a colorless transparent vial.
1 vial, 10 vials
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Celix Co., Ltd.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Boryung Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 0.5g
Prescription medication
(Boryung)
Ceftriaxone Sodium Hydrate 1g
Prescription medication
(Co., Ltd.) Joongheun Pharmaceutical
Ceftriaxone Sodium Hydrate 1g
Injections · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 500mg
Prescription medication
International Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.